Mineralys Therapeutics (MLYS) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 116.5% versus a loss of 40.3%. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $1.98 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | MRVI |
|---|---|---|
| Share price | $22.38 | $7.21 |
| Market cap | $1.98B | $2.67B |
| 1-day change | +1.31% | -2.96% |
| YTD return | -38.33% | +121.85% |
| 1-year return | -40.30% | +116.52% |
| 5-year return | — | -80.56% |
| EPS (TTM) | $-4.22 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-154.65M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $47.65 | $9.42 |
| 52-week low | $21.46 | $2.55 |
| Distance from 52-week high | -53.03% | -23.46% |
| Analyst consensus | none | buy |
| Avg. price target upside | +116.71% | +8.60% |
| Average volume | 1.03M | 3.36M |
| Shares outstanding | 88.41M | 148.99M |
| Employees | 76 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed MLYS by 156.8 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
MLYS vs MRVI FAQ
Which is bigger, Mineralys Therapeutics or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $1.98B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or MRVI?
MRVI returned +116.52% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.